Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Condition:   Type 2 Diabetes Treated With Insulin Interventions:   Drug: Insulin glargine;   Drug: NovoLog;   Drug: Insulin Fiasp;   Other: Standard carbohydrate diet Sponsors:   Boston Medical Center;   Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise
Conditions:   Insulin;   Exercise Interventions:   Drug: Placebo into the intranasal mucosa;   Drug: 20 IU NovoLog Insulin aspart into the intranasal mucosa;   Drug: 40 IU NovoLog Insulin aspart into the intranasal mucosa;   Drug: 60 IU NovoLog Insulin aspart into the intranasal mucosa;   Drug: 80 IU NovoLog Insulin aspart into the intr anasal mucosa;   Drug: 100 IU NovoLog Insulin aspart into the intranasal mucosa;   Drug: 120 IU NovoLog Insulin aspart into the intranasal mucosa Sponsor:   Michigan State University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 3, 2020 Category: Research Source Type: clinical trials

PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog ®/NovoRapid® in Healthy Males
Condition:   Diabetes Mellitus, Type 1 Intervention:   Drug: Gan & Lee Insulin Aspart Sponsor:   Gan and Lee Pharmaceuticals, USA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2020 Category: Research Source Type: clinical trials

The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study
Condition:   Type1 Diabetes Mellitus Interventions:   Device: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog;   Other: Usual Care Sponsor:   Massachusetts General Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2019 Category: Research Source Type: clinical trials

Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus
Condition:   Type 1 Diabetes Interventions:   Drug: SAR341402;   Drug: Insulin Aspart Sponsor:   Sanofi Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials